How are medications selected for the ACTIV-6 study?
ACTIV-6 is part of the National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of the most promising treatments and vaccines for COVID-19.

A selection committee was established to decide which medications to investigate in all ACTIV studies. This 20-member group included academic experts in COVID-19 research and anti-viral medications, members of non-profits supporting COVID-19 research, private-sector industry members, NIH employees, and employees from other U.S. government agencies. The group identified existing medications for further investigation using pre-established review criteria, data from laboratory and clinical research studies, and safety information.

What are repurposed medications?
The ACTIV-6 study is looking at repurposed medications in the search for effective, safe treatments for people with mild-to-moderate COVID-19 who are not hospitalized. Repurposed medications are those already approved by the U.S. Food and Drug Administration (FDA) to treat other health conditions, have been shown to be safe in humans, and are being tested for use in treating other conditions such as COVID-19.

Why is this study important?
There are treatments for people with severe COVID-19 who are at high risk for hospitalization or death, but they are complex to administer. Currently, there are no approved prescription medications that can be easily given at home to treat mild-to-moderate symptoms of the virus early in its course to prevent worsening of COVID-19.

What is fluticasone furoate?
Fluticasone furoate is an inhaled anti-inflammatory medicine commonly prescribed to treat asthma and chronic obstructive pulmonary disease (COPD).

Why is this medication part of the ACTIV-6 study?
Inhaled steroids are used to treat asthma or emphysema by reducing inflammation in the lungs that can cause breathing problems. COVID-19 may cause similar breathing problems. Inhaled medications’ potential effects when delivered directly to the lungs and their potential effects on the virus itself, have been evaluated in several small trials, showing potential benefit in COVID-19. A previous trial reported that the use of one inhaled steroid shortened symptom duration in patients with COVID-19. ACTIV-6 is studying fluticasone furoate, a different inhaled steroid, in non-hospitalized people with mild-to-moderate COVID-19, to determine if a different inhaled steroid could have the same benefit. The study will provide data to evaluate the medication’s safe and effective use for COVID-19 treatment.

The surveys you complete about your COVID-19 symptoms will help to inform the scientific community if this medication is appropriate for use in people with mild-to-moderate COVID-19 who are recovering at home.